L3VLUP
ProSign in

TNDM · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TNDMVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TNDM
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterTNDMVRTX
Q3 202013 holders, $1.7bn31 holders, $21.9bn
Q4 20206 holders, $1.1bn30 holders, $18.4bn
Q1 20219 holders, $943m31 holders, $15.4bn
Q2 202110 holders, $1.1bn30 holders, $12.7bn
Q3 202113 holders, $1.5bn35 holders, $10.1bn
Q4 202116 holders, $1.9bn28 holders, $12.4bn
Q1 202213 holders, $1.4bn23 holders, $16.1bn
Q2 202210 holders, $740m25 holders, $18.1bn
Q3 20228 holders, $748m22 holders, $18.4bn
Q4 202211 holders, $836m28 holders, $18.4bn
Q1 202310 holders, $411m26 holders, $21.4bn
Q2 20239 holders, $306m27 holders, $24.7bn
Q3 20236 holders, $256m33 holders, $24.3bn
Q4 20238 holders, $388m32 holders, $28.6bn
Q1 20249 holders, $426m31 holders, $29.8bn
Q2 20247 holders, $332m29 holders, $33.4bn
Q3 20247 holders, $295m27 holders, $33.5bn
Q4 202410 holders, $188m26 holders, $28.5bn
Q1 20254 holders, $44m21 holders, $35.4bn
Q2 20257 holders, $74m21 holders, $32.3bn
Q3 20256 holders, $64m22 holders, $25.9bn
Q4 20255 holders, $81m26 holders, $31.8bn
Q1 20265 holders, $69m25 holders, $31.8bn
Q2 20266 holders, $73m26 holders, $34.6bn
TNDM

Tandem Diabetes Care Inc

Holders
10
Reported value
$188m
Buyers
7
Sellers
2

Breadth +5 among 94 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$28.5bn
Buyers
14
Sellers
13

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 31 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TNDM (5)

Freestone Grove Partners LP, Moore Capital Management LP, Point72 Asset Management LP, Two Sigma Advisers LP, Two Sigma Investments LP

Only VRTX (21)

AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Capital Research Global Investors, D. E. Shaw & Co., Fidelity (FMR LLC), Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, MFS Investment Management, Millennium Management LLC, Neuberger Berman Group LLC, PDT Partners LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Voloridge Investment Management LLC, Wellington Management Group LLP, Winton Group Ltd, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →